Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Alabama for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Alabama only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Alabama (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Lakshmikanth Katragadda (NPI 1336303940)

Field	Value
Entity Type	Individual
Organization	Lakshmikanth Katragadda
Address	3601 Cci Dr Nw
City	Huntsville
State	AL
ZIP	35805
Taxonomy	Hematology & Oncology Physician
NPI Enumerated	July 12, 2008

Payer Source	Total Paid
Medicare	$2.1M
Medicaid	$0

Key Findings

Provider is effectively single-payer in the public programs: lifetime Medicare revenue is $2.1M and there is no Medicaid billing on file, so Medicare accounts for the entirety of the documented public-payer volume for this NPI. This concentration means analyses of utilization and revenue risk should focus on Medicare policy and reimbursement changes.

Revenue is highly concentrated in a few high-cost oncology drugs: the precomputed top-3 Medicare codes account for 63.2% of this provider's Medicare revenue, driven by J9271 ($894.4K, 46.4%), J1568 ($180.9K, 9.4%) and Q5127 ($143.1K, 7.4%). Operationally and financially, fluctuations in utilization or pricing for these specific products would materially affect the provider's Medicare revenue.

The code mix indicates an infusion-centric hematology/oncology practice: high revenue from J9271 (pembrolizumab), J1568 (IV immune globulin), and multiple chemotherapy and infusion administration codes such as 96413, 96365 and G0498 suggests routine outpatient administration of systemic oncology therapies. Supportive-care biologics and injectables (Q5127, J0897) combined with frequent infusion administration codes point to a clinic-focused treatment model rather than primarily procedural or surgical oncology.

Competitive standing on the leading drug codes is modest-to-strong but not dominant nationally: J9271 ranks #358 of 1841 providers (80th percentile, labeled typical), J1568 ranks #88 of 381 (77th percentile, typical), and Q5127 ranks #11 of 30 (66th percentile, typical). These ranks imply the provider has meaningful volume in these biologics relative to peers, but is not among the top national leaders for these products.

There are notable utilization outliers in evaluation-and-management and certain procedural codes that suggest heavy clinic throughput: 99214 has 1.6K claims and $142.6K revenue and is described as an "extreme outlier" at the 99th percentile, while chemotherapy administration 96413 (586 claims, $54.5K, 94th percentile) and infusion add-on 96375 (1.1K claims, $11.7K, 97th percentile) are labeled as notably above typical. These patterns are consistent with high visit volume and repeated infusion-based care delivery.

Lab and monitoring services represent a steady, high-volume ancillary revenue stream that supports oncology workflows: codes such as 80053 (2.5K claims, $25.3K, 98th percentile), 85025 (2.7K claims, $21.4K, 98th percentile), and 36415 (2.5K claims, $20.4K, 99th percentile) show routine in-office or ordered lab work used alongside therapeutic infusions. This suggests built-in clinical processes for frequent laboratory monitoring that also contribute to non-drug revenue.

Dependence on a single drug for a large share of revenue creates operational sensitivity: J9271 alone represents $894.4K and 46.4% of Medicare revenue, so policy, coverage, or utilization shifts affecting pembrolizumab would disproportionately impact the provider's Medicare topline. Payor negotiations or prior-authorizations focused on high-cost immunotherapies should be a monitoring priority.

Provider has long tenure in Medicare billing which supports stability in observed patterns: NPI enumerated 2008-07-12 (~18 years ago), indicating an established presence in Huntsville, AL. The combination of long registration, concentrated Medicare revenue of $2.1M, and a treatment-heavy code mix suggests an established outpatient oncology practice with stable operational routines.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

87 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	20,800	$40	$894.4K
J1568	Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg	5,320	$30	$180.9K
Q5127	Injection, pegfilgrastim-fpgk (stimufend), biosimilar, 0.5 mg	530	$270	$143.1K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	1,550	$90	$142.6K
J0897	Injection, denosumab, 1 mg	7,140	$20	$128.5K
J1437	Injection, ferric derisomaltose, 10 mg	4,400	$20	$74.8K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	590	$90	$54.5K
Q5108	Injection, pegfilgrastim-jmdb (fulphila), biosimilar, 0.5 mg	370	$100	$38.3K
J1454	Injection, fosnetupitant 235 mg and palonosetron 0.25 mg	90	$350	$30.9K
80053	The lab analyst performs a comprehensive metabolic panel, or CMP test in which he measures the blood level of 14 chemicals the code descriptor lists for the panel.	2,530	$10	$25.3K

Showing 1–10 of 87

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 87 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Alabama Distribution

Lakshmikanth Katragadda — 10 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Alabama

Full comparison — all codes billed, vs. state median

87 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	14	30	19,900	$40	$827.2K
J1568	17	30	5,180	$30	$316.2K
Q5127	9	20	590	$270	$165.7K
J0897	48	200	3,120	$20	$97.7K
J1437	10	40	3,000	$20	$59.1K
Q5108	4	10	370	$100	$38.1K
J1454	14	20	90	$340	$33.7K
J0881	16	30	7,720	$1	$24.1K
96413	11	150	150	$90	$20.2K
99214	43	7,330	120	$80	$16.8K

Showing 1–10 of 87

Related Providers

Other providers that share a Tax Identification Number (TIN) with Lakshmikanth Katragadda, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
John Waples	AL	Medical Oncology Physician	$9.6M	$0
Marshall Schreeder	AL	Medical Oncology Physician	$3.5M	$0
Heather Brody	AL	Hematology & Oncology Physician	$3.1M	$0
Jorge Diaz	AL	Hematology & Oncology Physician	$2.6M	$0
Naveen Lobo	AL	Medical Oncology Physician	$2.4M	$0
Ali Hachem	AL	Hematology & Oncology Physician	$2.3M	$0
Daniel Schreeder	AL	Hematology & Oncology Physician	$2.3M	$0
Robert Conry	AL	Hematology & Oncology Physician	$2.1M	$0
Oncology Specialties, P.C.	AL	Hematology & Oncology Physician	$0	$2M
Surrinder Dang	AL	Hematology & Oncology Physician	$1.9M	$0

Nearby Providers

Other providers in the same ZIP code as Lakshmikanth Katragadda, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Huntsville Emergency Medical Services, Inc.	AL	Land Ambulance	$5.6M	$6M
Madison Core Laboratories, LLC	AL	Clinical Medical Laboratory	$1.5M	$4M
Hc Healthcare, LLC	AL	Community Based Hospice Care Agency	$0	$4.8M
The Village Medical Clinic	AL	Specialist	$0	$2M
Ehab El-bahesh	AL	Hematology & Oncology Physician	$1.7M	$0
Pathology Associates, P.C.	AL	Anatomic Pathology & Clinical Pathology Physician	$0	$1.7M
Rehabilitation & Neurological Services LLC	AL	Specialist	$0	$1.3M
Philip Mcgee	AL	Hematology & Oncology Physician	$1.2M	$0
John Nicholson	AL	Hematology & Oncology Physician	$1.2M	$0
Elizabeth Falkenberg	AL	Radiation Oncology Physician	$1.1M	$0

Lakshmikanth Katragadda — Billing Profile & Reimbursement Data

Sign up for Lakshmikanth Katragadda — Billing Profile & Reimbursement Data policy alerts

Lakshmikanth Katragadda — Billing Profile & Reimbursement Data

Sign up for Lakshmikanth Katragadda — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References